QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
ISPOR 2026
Starting Day 1 of ISPOR with the full team from the athagoras Group… We are looking forward to connecting with clients, new and old, colleagues and building new relationships.
Watch this space!
Growing talent in evidence research
A strong research career often starts with curiosity and consistency.
We are happy to share that Sanjana has transitioned from intern to Research Analyst within Quantify Research’s Evidence Review and Synthesis team in India.
Since joining as an intern in October 2025, she has contributed to systematic literature reviews and evidence synthesis projects while continuing her academic journey in Pharmacology at Panjab University, Chandigarh.
Her GPAT and NIPER qualifications further reflect her dedication […]
The team heading to ISPOR 2026
Quantify Research will be attending ISPOR 2026 in Philadelphia (17–20 May) as part of the athagoras Group.
Joining from Quantify:
• Puneet Kaushik
• Kelsi Smith
• Abraham Choong
Together with our athagoras Group colleagues:
▪️Giuseppe Pileggi
▪️Agata Daroszewska
▪️Mattias Kyhlstedt
▪️Thomas Frei
▪️Thomas Ecker
▪️Chus Castillo Gutierrez
📍 You can find us at Booth #436
We are looking forward to conversations on:
➡️ Supporting market access across Europe and the […]
Rare disease HTA: TLV accepts an ICER above 2 million SEK/QALY
TLV’s recent decision on Fabhalta provides further evidence of how Sweden applies higher acceptable ICERs in very rare conditions.
Fabhalta was assessed for a very rare, severe chronic kidney disease population. Following three-party negotiations, TLV’s base case, including the confidential agreement, resulted in:
➡️ ICER: 2,035,738 SEK/QALY
➡️ QALY gain: 3.91
➡️ Rarity index: 56–85
➡️ Outcome: reimbursement with restriction
You can read the official decision here
And the full HTA report here
Why is […]
